The Role of Serum Pepsinogen and Gastrin Test for the Detection of Gastric Cancer in Korea
- 5 March 2008
- journal article
- Published by Wiley in Helicobacter
- Vol. 13 (2), 146-156
- https://doi.org/10.1111/j.1523-5378.2008.00592.x
Abstract
This study was performed to determine whether serum pepsinogen (PG) and gastrin testing can be used to detect gastric cancer in Korea. Serum levels of PG I (sPGI) and sPGII, PG I/II ratios, and gastrin levels were measured in 1006 patients with gastroduodenal diseases including cancer. Follow-up tests were performed 1 year after Helicobacter pylori eradication. sPGI and sPGII levels increased and PG I/II ratios decreased in line with the severity of activity, chronic inflammation, and the presence of H. pylori (p < .01). In contrast, sPGI levels and PG I/II ratios decreased in proportion with the severity of atrophic gastritis (AG)/intestinal metaplasia (p < .01). Gastrin levels were found to be correlated with chronic inflammation negatively in the antrum but positively in the corpus. H. pylori eradication reduced sPGI, sPGII, and gastrin levels, and increased PG I/II ratios to the levels of H. pylori-negative patients, and was found to be correlated with reductions in activity and chronic inflammation of gastritis. The sensitivity and specificity of a PG I/II ratio of < or = 3.0 for the detection of dysplasia or cancer were 55.8-62.3% and 61%, respectively. In addition, sPGI and sPGII levels of intestinal-type cancer were significantly lower than those of the diffuse type, respectively (p = .008 and p = .05, respectively). Gastric cancer risk was highest in the H. pylori-positive, low PGI/II ratio (< or = 3.0) group with an odds ratio of 5.52 (confidence interval: 2.83-10.77). PG I/II ratio (< or = 3.0) was found to be a reliable marker for the detection of dysplasia or gastric cancer, especially of the intestinal type. This detection power of PG I/II ratio (< or = 3.0) significantly increased in the presence of H. pylori, and thus, provides a means of selecting those at high risk of developing gastric cancer in Korea.Keywords
This publication has 67 references indexed in Scilit:
- Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori statusGut, 2007
- Gastric cancer screening using the serum pepsinogen test methodGastric Cancer, 2006
- The relation of pepsinogen group II (PGII) expression to intestinal metaplasia and gastric cancerHistopathology, 2006
- Hypergastrinemia after Helicobacter pylori infection is associated with bacterial load and related inflammation of the oxyntic corpus mucosaJournal of Gastroenterology and Hepatology, 2004
- Improvement in serum pepsinogens and gastrin in long‐term monitoring after eradication of Helicobacter pylori: comparison with H. pylori‐negative patientsAlimentary Pharmacology & Therapeutics, 2004
- Molecular basis of gastric carcinogenesisAlimentary Pharmacology & Therapeutics, 2003
- Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspepticsBritish Journal of Cancer, 2003
- Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South KoreaJournal of Gastroenterology and Hepatology, 2001
- The Significance of Low Serum Pepsinogen Levels to Detect Stomach Cancer Associated with Extensive Chronic Gastritis in Japanese SubjectsJapanese Journal of Cancer Research, 1989
- Clinical significance of pepsinogen a isozymogens, serum pepsinogen A and C levels, and serum gastrin levelsCancer, 1987